Medical inquiries

Connect with my medical science liaison

Chat live

Available Monday - Friday 9AM - 4:30PM ET

Call me now

Available Monday - Friday 9AM - 7:30PM ET

Email your inquiry

Call 1-800-526-7736

Available Monday - Friday 9AM - 8PM ET

Live video

Available Monday - Friday 9AM - 4:30PM ET

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

SPRAVATO® (esketamine)

Medical Information

+ Save link

Direct Absorption of SPRAVATO to CNS - No Data

Last Updated: 01/17/2025

SUMMARY

Nose-to-brain delivery was not studied; however, it is not considered relevant for SPRAVATO nasal spray. The wide plume angle produced by the nasal spray device delivers medication mainly to the respiratory epithelium, leading to uptake of drug into the bloodstream.¹ A population pharmacokinetic analysis showed that after nasal administration of an initial dose of esketamine 28 mg, 54% of the dose was absorbed through the nasal cavity, whereas 46% was swallowed.²

Literature Search

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and Derwent Drug File (and/or other resources, including internal/external databases) pertaining to this topic was conducted on 17 December 2024.

References

Show

1	Data on File. Esketamine. Internal Communication.
2	Perez-Ruixo C, Rossenu S, Zannikos P, et al. Population pharmacokinetics of esketamine nasal spray and its metabolite noresketamine in healthy subjects and patients with treatment-resistant depression. Clin Pharmacokinet. 2021;60(4):501-516.